Latest Wearables News

dorsaVi Ltd is expanding its RRAM technology evaluation to next-generation robotics, aiming to deliver sub-millisecond reflexes that could revolutionize safety and dexterity in collaborative robots and wearables.

Control Bionics capped a record FY25 with 15% revenue growth, driven by US market gains and expanding NeuroNode and NeuroStrip technologies. The company also achieved a US profitability milestone and is close to finalizing key distribution partnerships.

TrivarX has secured key approvals and begun recruiting for its innovative mental health screening trial in US veterans, while also launching a wearable tech pilot with a Major League Baseball academy in the Dominican Republic.

Alterity Therapeutics has secured U.S. FDA Fast Track designation for its drug ATH434 targeting Multiple System Atrophy, supported by promising Phase 2 clinical trial data showing slowed disease progression and a solid safety profile.

dorsaVi has acquired exclusive global rights to advanced RRAM technology, promising major performance gains in its biomedical sensors, while securing key contracts and raising $2.44 million to fuel US market growth.

Vitasora Health Limited reported a remarkable 226% increase in patient programs and secured an $11 million capital raise, positioning the company for accelerated growth and a path to cash flow breakeven in late 2026.

Spacetalk Ltd reports robust growth in paid mobile subscribers and recurring revenue for Q4 FY25, supported by strategic capital raises and international expansion.

dorsaVi reports transformative performance improvements from integrating RRAM technology into its biomedical sensor platforms, promising faster, more durable, and energy-efficient wearable devices.

dorsaVi confirms its licensed 40nm Resistive RAM technology delivers high-speed, low-power performance ideal for next-generation embedded and edge AI platforms. This breakthrough supports advanced wearable sensors and neuromorphic computing applications.

Spacetalk Ltd has raised $3 million through convertible notes from its largest shareholder and converted $1 million of secured debt, positioning the company for international growth and new product development.

Nanoveu Limited has showcased its acquisition of EMASS and the breakthrough ECS-DoT system-on-chip technology, promising ultra-low-power AI processing with a notable 33% simulated flight time improvement in drones.

Nanoveu’s subsidiary EMASS has reached a key milestone by moving its ECS-DoT AIoT chip into 16nm synthesis, while unveiling a Modular AIoT Development Kit to accelerate edge intelligence adoption.